EFdA-p + Progestin Intravaginal Film
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Vaginal Gel
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Magee-Women's Research Institute, University of Pittsburgh
Details
- API: 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine (EFdA) Prodrug, Levonorgestrel or Etonogestrel
- Target: Progesterone Receptor
-
Mechanism of Action:
- Endometrial Changes
- Cervical Mucus Changes
- Inhibition of Sperm Motility
- Ovulation Inhibition
- Anti-Microbial
- Regimen: 1 Film/Month
- MPT: Potential MPT
- Promising Attributes: The method offers both pregnancy prevention and HIV prevention.
Product Status
Active Pre-Clinical Research
History
2019-2023: NIH grants awarded to optimize the MPT film formulation to achieve one-month delivery of both drugs, establish the compatibility of film prototype with vaginal tissue and microbial flora in vitro, and demonstrate the ability of the MPT film prototype to attain desired release profiles of both drugs in vivo. IND-enabling safety and pharmacokinetic targets have been met, supporting potential future clinical evaluation.